MEMagda Esebua

Magda Esebua

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Magda Esebua has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Endobronchial Ultrasound Guided Transbronchial Needle Aspiration of Solitary Lung Nodules and the Triple Diagnosis Technique: Does Triple Diagnosis Improve Diagnostic Accuracy?

    by Jason Sinclair, Peace Preston, Magda Esebua, Van Nguyen, Carla Caruso, Jeffrey Kunin, Lester J. Layfield

    Background: Endobronchial ultrasound guided Transbronchial Needle Aspiration (EBUS‐TBNA) is the predominant method for investigation of centrally located solitary pulmonary nodules. The method is associated with good to excellent diagnostic sensitivity and specificity with the positive predictive value of the test reaching 100% and reported negative predictive values for FNA of pulmonary nodules ranging from 53% to 97%. The impact of correlating cytologic results with imaging and clinical findings for improvement of negative predictive value has been poorly studied.Materials and Methods: An electronic search of the cytology records of the University of Missouri was made for all EBUS‐TBNA specimens with surgical pathology follow‐up. The associated imaging and clinical impressions were obtained. The clinical impression/assessment was the assessment given in the clinical summary section of the clinical note. Results of each technique were designated as benign, indeterminate, or malignant. Diagnostic triplets were constructed, and calculation of sensitivity, specificity, positive predictive value and negative predictive value was performed for each modality as well as the triplets.Results: Search revealed a total of 254 cases with definitive surgical follow up. Thirty‐two of these were excluded because they were either cytologically non‐diagnostic or fell into one of the intermediate categories. One hundred sixty‐three and 84 of these cases had definitive imaging or clinical interpretive results respectively. Definitive diagnostic triplets were obtained in 58 cases (22.8%). Cytology was associated with a sensitivity of 66.7% and specificity of 81.1%. Its positive predictive value was 87.7% and its negative predictive value was 54.5%. Imaging was associated with a sensitivity of 90.7%, a specificity of 22.2%, a positive predictive value of 75.4% and a negative predictive value of 47.6% and these statistics were 96.7%, 33.3%, 78.4%, and 80.0% respectively for clinical analysis. The positive predictive value of a triplet analysis was 92.9% and the negative predictive value was 100%.Conclusions: Diagnostic triplets were obtainable in only a minority of cases, but they resulted in significant improvement in positive and negative predictive values.


  • World Health Organization Reporting System for Soft Tissue Cytopathology: Risk of malignancy and reproducibility of categories among observers

    by Lester J. Layfield, Leslie Dodd, Magda Esebua

    Introduction: In 2024, the World Health Organization (WHO) is scheduled to publish the WHO Reporting System for Soft Tissue Cytopathology (WHORSSTC). This system establishes categories with well‐defined definitions, criteria, and estimated risks of malignancy (ROMs) for soft tissue tumors. The estimates of ROM are based on a relatively small number of published studies. Interobserver reproducibility is not addressed in the reporting system even though reproducibility of a reporting system is highly important.Methods: A manual search of one authors personal consultation files and teaching set (L.J.L.) was conducted for all cytologic specimens of soft tissue tumors accessioned between January 1, 1985 and December 31, 2022. Only cases with documented surgical pathology follow‐up were included in the study. Slides from each case were evaluated independently by three cytopathologists with each case assigned to one of the WHORSSTC categories. A ROM for each of the WHORSSTC categories was calculated. Interobserver agreement was evaluated by the kappa and weighted kappa statistics.Results: Risk for malignancy by category were: Category 1: 0%, Category 2: 28%, Category 3: 57%, Category 4: 47%, Category 5: 63%, and Category 6: 88%. Kappa statistics for agreement between raters varied from 0.2183 to 0.3465 and weighted kappa varied from 0.3778 to 0.5217.Conclusions: The WHORSSTC showed a progression of malignancy risk from the category “benign” (28%) to the category “malignant” (88%). Interobserver agreement was only fair.


  • Molecular testing of cytology specimens: Issues in specimen adequacy and clinical utility

    by Ghulam Ghous, Komal Ijaz, Magda Esebua, Lester J. Layfield

    Background: Next generation sequencing (NGS) is standard of care for workup of many neoplasms including adenocarcinomas of the lung. Molecular testing of cytology samples is used for many types of neoplasms but the value of such testing for the selection of “first”‐ and “second‐line” treatment protocols is incompletely understood.Methods: Fifty‐six sequentially performed cytology specimens (49 fine needle aspirates and 7 fluids) submitted for molecular analysis were reviewed by a medical oncologist to determine specimen adequacy and utility of results for therapy selection. Chart review was performed to determine availability of microsatellite instability status, tumor mutational burden, and presence of driver mutations treatable with targeted therapy in a “first”‐ or “second‐line” application.Results: Forty of 56 cases were successfully sequenced and 34% (19/56) had targetable mutations detected by NGS. Ten of these 19 cases (53%) received targeted therapy for their tumor type with five of 10 patients receiving “first‐line” therapy and five (50%) “second‐line” therapy. Twenty‐two mutations were detected where no targeted therapy for the patient's tumor type existed but targeted therapies were available for other tumor types. Of these specimens, only one patient received treatment using protocols associated with a second tumor type. Total mutation burden and microsatellite instability status results were obtained in 29 of 56 cases (52%).Conclusions: 71% (40/56) of cytologic specimens were adequate for sequencing with 34% (19/56) demonstrating a targetable mutation and 53% of these patients receiving therapy targeted to the driver mutation of their tumor type.

  • Diagnosis of salivary gland tumors: Does the triple diagnosis method have value?

    by Peace Preston, Magda Esebua, Lester J. Layfield

    Background: Appropriate clinical management of salivary gland lesions requires a determination as to whether a salivary gland nodule is benign or malignant. Approximately three‐quarters of all salivary gland nodules represent benign neoplasms. Separation of salivary gland carcinomas from benign lesions can be diagnostically challenging. The Milan System for Reporting Salivary Gland Cytopathology recommends the correlation of cytologic diagnoses with imaging and clinical findings creating a diagnostic triplet. How often the “Triple Diagnosis” method is used and its accuracy in separating salivary gland nodules into benign and malignant groups are unknown.Methods: An electronic records search of cytology files at the University of Missouri was performed for fine needle aspirates of the salivary gland obtained between September 2018 and August 2022. Chart review was performed for preoperative clinical and imaging diagnoses. Diagnostic “Triplets” constructed from cytologic, clinical, and imaging diagnoses were correlated with final surgical pathology diagnosis.Results: One hundred and thirty‐six FNAs were identified. Eighty‐seven cases had preoperative imaging with 52 of these cases having clinical diagnoses. Due to the lack of a definitive clinical or imaging diagnosis for a nodule as benign or malignant, only 12 (23%) cases had definitive “Triplets.” Nine (17%) “Triplets” were benign and three (6%) were malignant. Accuracy of concordant triplets was 100% for the prediction of malignancy and 89% for the prediction of a benign result as determined by final histologic diagnoses.Conclusion: While highly accurate in predicting the benign or malignant nature of a salivary gland nodule, concordant triplets made up only 23% of cases limiting their clinical utility.


  • Molecular testing in cytology

    by Fernando Schmitt, Zhongbo Yang, Magda Esebua

    In the era of personalized medicine, molecular testing plays a critical role in patient care. The rapid advance of molecular techniques, especially next‐generation sequencing, makes molecular diagnosis feasible in daily practice. Molecular testing can be used as a valuable ancillary test to increase diagnostic sensitivity and specificity, especially in small biopsy or cytology samples. In addition, molecular testing plays an important role in selecting patients for appropriate treatment by detecting therapeutic and predictive biomarkers in tissue or cytology samples. Molecular studies can be applied in all cytology samples, sometimes with better results than histology. As molecular testing has become essential for patient care and is often requested to be performed in cytology samples, it is critical for cytopathologists to understand the basics of molecular diagnostic methods, indications for molecular testing, and how to best utilize different cytologic samples for this purpose. In this special issue, experts in various areas of cytopathology and molecular pathology review the literature and discuss the basics of molecular techniques and the application of molecular testing in various types of cytology samples. It is our hope that after reading the articles in this special issue, the readers can know better about the possibilities of molecular cytology, a very exciting field of pathology.


  • PD‐L1 immunohistochemical testing: A review with reference to cytology specimens

    by Lester J. Layfield, Tao Zhang, Magda Esebua

    Background: Immunotherapy based on disruption of the PD‐1/PD‐L1 axis is standard of care for many high stage malignancies including melanomas, non‐small cell carcinomas of the lung, triple negative breast carcinomas, and squamous cell carcinomas of the head and neck. Eligibility for immunotherapy requires immunohistochemical assessment of PD‐L1 expression. Currently, many high stage malignancies are diagnosed by cytology and cytologic material is the only specimen available for ancillary testing. Formal guidelines do not currently exist defining the optimal specimen type, antibody to be used or the best scoring system for cytologic material. Significant information has been published for PD‐L1 testing of pulmonary specimens but much less data exists for the reproducibility, accuracy and best practices for material obtained from other body sites and types of malignancy.Methods: We searched the PubMed data base for manuscripts relating to PD‐L1 testing of cytologic specimens. The search period was between 2016 and 2022. The search terms used were PD‐L1, cytology, FNA, immunotherapy, immunohistochemistry, immunocytochemistry, cytology‐histology correlation. Cross referencing techniques were used to screen for the most relevant manuscripts. The abstracts of these were then reviewed for final data collection and analysis.Results: A total of 86 studies were identified conforming to study relevancy. These were reviewed in their entirety by two authors (LJL, TZ) for extraction of data. The majority of studies involved pulmonary specimens (79) with three relating to PD‐L1 testing of head and neck cytologic specimens and one each for PD‐L1 testing of cytology specimens from melanomas, pancreas, pleural fluids, and triple negative breast carcinomas. While smears could be used, most studies found cell blocks optimal for testing.Summary: Currently, four drugs are approved for immunotherapy based on PD‐L1 status. These drugs require specific antibody clones as well as scoring systems. Scoring systems and cut points vary with the type of neoplasm being treated. Cytology specimens from the lung, head and neck and melanomas can all be used for PD‐L1 testing with good agreement with corresponding histology specimens.


  • Core needle biopsy for the diagnosis of primary soft tissue lesions: Accuracy and diagnostic challenges

    by Lester J. Layfield, Paul Stegelmeier, Liangli Wang, Magda Esebua

    Background: Core needle biopsy (CNB) and fine needle aspiration (FNA) are currently the most common biopsy methods for investigation of soft tissue lesions. Selection of the method to be used depends on a number of factors including diagnostic accuracy, local expertise with the techniques and the need for ancillary testing. We investigated the diagnostic accuracy of CNB and factors influencing the selection of CNB or FNA.Methods: An electronic search of the surgical pathology records for all core needle biopsies of soft tissue lesions with subsequent incisional biopsies or excisions between January 1, 2015 and December 31, 2021 was performed. Searches of the literature for publications documenting diagnostic accuracy of core biopsy and FNA were performed using the Pub Med literature data base.Results: The electronic search yielded 177 CNBs with appropriate follow‐up. Six cases were non‐diagnostic. The remaining 171 cases showed an accuracy of 90% for separation of benign from malignant with two false‐positive and 17 false‐negative diagnoses. The literature search revealed 11 series of CNBs with a diagnostic accuracy of 74% to 97%. The literature search revealed 20 series of FNAs with an accuracy of 84.8% to 100% for separation of benign from malignant.Conclusions: Core needle biopsy is a highly accurate diagnostic technique with an accuracy of 90% for separation of benign from malignant lesions. The percentage of non‐diagnostic cases is low (3.4%). No significant biopsy related complications were seen in this study.


  • Molecular features of pancreaticobiliary neoplasms: Implications for diagnosis, prognostication, and therapy selection

    by Lester J. Layfield, Tao Zhang, Magda Esebua

    Background: Molecular diagnostics has impacted the diagnosis, prediction of prognosis, and selection of targeted therapy for many tumor types. While pulmonary adenocarcinomas and melanomas are among the neoplasms most associated with molecular diagnostics and targeted therapy, malignancies of the pancreaticobiliary system have also been impacted by precision medicine.Methods: We undertook an electronic search using PubMed and Embase to review the published literature to determine what forms of molecular testing, mutations and oncogenetic pathways are associated with neoplasms of the pancreaticobiliary system. Keywords utilized were pancreas, bile duct, mutations, ERCP, FNA, KRAS, SMAD4, TP53, next‐generation sequencing, serous cystadenoma, pancreatic ductal adenocarcinoma, intraductal papillary mucinous neoplasm, cystic mucinous neoplasm, solid pseudo‐papillary neoplasm.Results: A search between 1999 and 2022 yielded 6874 manuscripts. Screening of these yielded 302 more focused manuscripts of which 55 were used for the study. Ductal adenocarcinoma of the pancreas is associated with a progression of mutations beginning wit KRAS mutations and ending with a set of mutations in the TP53, SMAD4, and DPC4 genes. Similar mutations are found in neoplastic mucinous cysts. Specific mutations characterize serous cystadenomas, solid, and pseudo papillary neoplasms and adenocarcinomas of the bile ducts.Conclusions: Mutational analysis of cytologic specimens obtained by fine‐needle aspiration, and duct brushings and washings are helpful in the diagnosis of pancreaticobiliary neoplasms and may supply prognostic information.


  • Salivary gland neoplasms with basaloid features in the era of the Milan system for reporting salivary gland cytology: Classification and interobserver agreement

    by Lester J. Layfield, Magda Esebua, Liron Pantanowitz, Zahra Maleki, Maryna Vazmitsel, Zubair Baloch, Richard L. Cantley, Robert Schmidt

    Background: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) has been shown to have moderate to good reproducibility for categorization of salivary gland fine‐needle aspiration (FNA) specimens. Less is known of its accuracy and interobserver reproducibility for categorization of the diagnostically difficult group of basaloid neoplasms.Methods: Forty‐five salivary gland specimens with a basaloid morphology (pleomorphic and monomorphic adenomas and adenoid cystic carcinomas) were independently assigned by seven cytopathologists to one of the MSRSGC categories. Interobserver agreement was assessed for average agreement, chance expected agreement and by Cohen's κ and diagnostic accuracy. Correlation of the salivary gland neoplasm of unknown malignant potential (SUMP) category with histologic diagnosis and benign or malignant designation along with interobserver reproducibility were calculated.Results: Average observed agreement for assignment to the MSRSGC was 46% and Cohen's κ = 0.2%. The SUMP category did not correlate with tumor type or with the benign or malignant nature of the neoplasm. Diagnostic specificity and sensitivity were 92% and 100% for consensus diagnosis, but were 76% and 77% for individual diagnoses.Conclusion: The interobserver agreement in categorizing basaloid neoplasms by the MSRSGC is poorer than for salivary gland lesions overall. This reflects the difficulty in diagnosing basaloid neoplasms. Nonetheless, diagnostic accuracy appears similar to that of salivary gland neoplasms as a whole.


  • Diagnostic sensitivity and risk of malignancy for bile duct brushings categorized by the Papanicolaou Society of Cytopathology System for reporting pancreaticobiliary cytopathology

    by Lester J. Layfield, Tao Zhang, Magda Esebua

    Background: The Papanicolaou Society of cytopathology developed a six‐category system for pancreaticobiliary cytology specimens. Each category is associated with a definition, diagnostic criteria, estimated risk of malignancy and management recommendations. Risks of malignancy are well defined for specimens obtained by fine‐needle aspiration but are less well defined for brushing specimens.Methods: Diagnoses of 232 brushing specimens of the pancreatic and bile ducts were correlated with diagnoses from subsequent surgical or cytologic specimens. Sensitivity for the brushing technique was calculated. Risk of malignancy was calculated for each category using the original definitions for nondiagnostic and negative categories and for those of a modified system.Results: Diagnostic sensitivity was 60%–64%. Risk of malignancy for the nondiagnostic, negative, atypical, suspicious for malignancy, and malignant categories was 28%, 28%, 61%, 91%, and 91%, respectively, when the original category definitions were used.Conclusions: Diagnostic sensitivity for duct brushings is low in comparison to fine‐needle aspiration. Risk of malignancy is comparable to that of needle aspiration for the negative, atypical and suspicious categories but lower for the malignant category. There is a stepwise increase in malignancy risk as one moves from the negative to the atypical to the suspicious for malignancy categories.